Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features.
Brimonidine tartarate is a selective alpha2-adrenergic receptor agonist that is indicated for use in the treatment of glaucoma and ocular hypertension. Since its introduction in 1997 there have been a small number of case reports concerning granulomatous anterior uveitis as a late adverse reaction to long-term brimonidine therapy. We report a case of bilateral anterior uveitis and granulomatous papillary conjunctivitis in a 78-year-old gentleman after 2 years of brimonidine therapy. Cessation of brimonidine lead to rapid termination of uveitis. The histologic features of the conjunctiva are described. This has not been previously reported.
Nguyen
Ethan V
EV
Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia. ethannguyen1983@yahoo.com
Azar
Domit
D
Papalkar
Daya
D
McCluskey
Peter
P
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000009:adverse effects*; D000368:Aged; D000068438:Brimonidine Tartrate; D003228:Conjunctiva / Q000473:pathology; D003231:Conjunctivitis / Q000139:chemically induced* / Q000175:diagnosis; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D006099:Granuloma / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D008297:Male; D011810:Quinoxalines / Q000009:adverse effects*; D014606:Uveitis, Anterior / Q000139:chemically induced* / Q000175:diagnosis
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D011810:Quinoxalines; D000068438:Brimonidine Tartrate